Imatinib Mesylate Tablet, Film Coated
Product Images NDC 82009-086

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 82009-086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Imatinib Fig1)

A line chart titled 'Progression Free Survival (ITT Principle)' showing percentage without progression over 72 months since randomization. It compares two groups: Imatinib Mesylate (solid line) and IFN+Ara-C (dashed line), with Imatinib Mesylate demonstrating higher survival percentages. The chart includes patient numbers with progression, censored cases at discontinuation and last follow-up, hazard ratio, confidence interval, and P-value for the log-rank test.*

FDA Label Image

Imatinib-fig2 (Imatinib Fig2)

A line graph titled "Time to Progression to AP or BC (ITT Principle)" comparing Imatinib Mesylate and IFN+Ara-C arms. The y-axis shows percentage without progression to AP/BC from day 0, and the x-axis shows months since randomization up to 72 months. The graph includes patient count data, hazard ratio with confidence interval, and p-value for statistical significance.*

FDA Label Image

Figure (Imatinib Fig3)

A line graph titled 'Study 1 Recurrence-Free Survival (ITT Population)' shows the probability of being alive and recurrence-free over survival time in months. It compares two groups, Imatinib 400 mg and Placebo, with Imatinib group showing higher survival probabilities over time. Censored data points are marked with circles and plus signs. At-risk patient counts are provided below the x-axis for both groups at various time intervals.*

FDA Label Image

Figure (Imatinib Fig4)

A Kaplan-Meier curve titled 'Study 2 Recurrence-Free Survival (ITT Population)' depicting the probability of recurrence-free survival over time in months for two treatment groups of Imatinib Mesylate. The graph shows survival probabilities on the y-axis (0-100%) versus survival time in months on the x-axis (0-84 months), with censored observations marked. The curve compares Imatinib treatment durations of 12 months and 36 months, illustrating survival outcomes and statistical data including hazard ratio and p-value.*

FDA Label Image

Figure (Imatinib Fig5)

Kaplan-Meier survival curve graph depicting overall survival probability over time in months for two groups treated with Imatinib Mesylate at 12 months and 36 months, from Study 2 (ITT Population). The graph includes survival probabilities on the vertical axis and survival time in months on the horizontal axis, with censored observations and risk event tables shown below.*

FDA Label Image

Package Label-principal Display Panel (100 mg)

Imatinib Mesylate Tablets 100 mg film-coated, 90 tablets per bottle, labeled for prescription use. The label indicates the product is manufactured for Quallent Pharmaceuticals LLC and by Eugia Pharma Specialities Limited in India. Storage instructions note to keep the product at 20° to 25°C and protect from moisture. The label includes dosage guidance to refer to the package insert and cautions to keep out of reach of children.*

FDA Label Image

Package Label-principal Display Panel (400 mg)

Imatinib Mesylate Tablets 400 mg film-coated tablets, packaged in a container of 30 tablets. The label indicates the product is manufactured for Quallent Pharmaceuticals LLC and by Eugia Pharma Specialities Limited in India. The label provides storage instructions, dosage reference, and safety information, including keeping the medication out of children’s reach.*

FDA Label Image

Chemical Structure (Imatinib Str)

Chemical structure of Imatinib Mesylate showing the arrangement of pyridine, benzamide, piperazine, and methylsulfonate functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.